Phase I Platinum Based Chemotherapy Plus Indomethacin
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are
recruited to the stroma of both the primary tumor and metastasis. Recent preclinical research
has shown that in response to platinum-based chemotherapy, MSCs secrete two specific
platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of
chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and
the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the COX-1
pathway. COX inhibitors, including indomethacin. This phase 1 study explores the safety of
combining indomethacin with platinum containing chemotherapy.